Study M1112
Study name | Singh B 2022b |
Title | Racemic ketamine treatment attenuates anterior cingulate cortex GABA deficits among remitters in treatment-resistant depression: a pilot study |
Overall design | In this study, seven patients with treatment-resistant depression enrolled in an open-label, feasibility trial of a single IV 40-min ketamine infusion during a functional MR spectroscopy scan. Patients were divided into remitters (remitter group; MADRS score =< 9; n = 3) and non-remitters (non-remitter group; n = 4) at 24 hours post-infusion. Dynamic changes of GABA and Glx in the anterior cingulate cortex was detected during the ketamine infusion. Metabolite quantification was reported in institutional units and relative to total creatine as the reference peak. |
Study Type | Type4; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Treatment-resistant depression; Treatment-resistant depression; |
Criteria for depression | DSM-5 diagnosed MDD, PHQ-9 >= 15 |
Sample size | 7 |
Tissue | Central; Brain; Anterior cingulate cortex; |
Platform | MRS; MRS: 3T Siemens MRI scanner (Siemens Medical Solutions USA, Inc., Malvern, Pennsylvania, USA); |
PMID | |
DOI | |
Citation | Singh B, Port JD, Pazdernik V, et al. Racemic ketamine treatment attenuates anterior cingulate cortex GABA deficits among remitters in treatment-resistant depression: a pilot study. Psychiatry Res Neuroimaging. 2022 Mar;320:111432. |
Metabolite |
